Skip to main content
Erschienen in: Tumor Biology 12/2014

01.12.2014 | Research Article

Single-nucleotide polymorphisms of the PRKCG gene and osteosarcoma susceptibility

verfasst von: Ying Zhang, Xu Hu, Hong-Kai Wang, Wei-Wei Shen, Tong-Quan Liao, Pei Chen, Tong-Wei Chu

Erschienen in: Tumor Biology | Ausgabe 12/2014

Einloggen, um Zugang zu erhalten

Abstract

The objective of this study was to explore the relationship between single-nucleotide polymorphisms (SNPs) of the protein kinase C gamma (PRKCG) gene and osteosarcoma susceptibility in Chinese Han population. A total of 610 cases of osteosarcoma patients and 610 healthy individuals were enrolled in this study. TaqMan method was used to compare genotypes and the allelic distribution frequency of three SNPs (rs454006, rs2242245, and rs8103851) in the PRKGG gene between osteosarcoma patients and healthy individuals. Osteosarcoma patients were grouped according to different clinical parameters (age, gender, pathological types, tumor location, Enneking staging, tumor metastasis and treatment) to compare genotype and allele frequency among different groups as well as to explore the relationship between gene polymorphisms and different clinical parameters. The rs454006 polymorphisms of the PRKCG gene include the CC, CT, and TT genotypes. The differences in genotype frequency and allele frequency between osteosarcoma patients and healthy individuals were significant (both P < 0.001). There was no significant different between osteosarcoma patients and healthy individuals in rs8103851 and rs2242245 polymorphisms of the PRKCG gene (both P > 0.05). The differences of the rs8103851 genotype frequency and allele frequency in patients with metastatic osteosarcoma and patients without metastasis were significant (both P < 0.001). The distribution frequencies of the CG and GG genotypes as well as the G allele in patients with metastatic osteosarcoma were higher than in patients without metastasis. The genotype frequency and allele frequency of rs454006 and rs2242245 did not correlate with clinical parameters. The rs454006 polymorphism of the PRKCG gene correlated to osteosarcoma susceptibility and might increase the risk of osteosarcoma. The rs8103851 correlated to metastatic osteosarcoma and could be risk factors for metastatic osteosarcoma.
Literatur
1.
Zurück zum Zitat Campanacci M. Bone and soft tissue tumors: clinical features, imaging, pathology and treatment. New York: Springer; 1999. p. 464–91.CrossRef Campanacci M. Bone and soft tissue tumors: clinical features, imaging, pathology and treatment. New York: Springer; 1999. p. 464–91.CrossRef
2.
Zurück zum Zitat Stiller CA, Bielack SS, Jundt G, et al. Bone tumours in European children and adolescents,1978–1997, report from the Automated Childhood Cancer Information System project. Eur J Cancer. 2006;42(2124). Stiller CA, Bielack SS, Jundt G, et al. Bone tumours in European children and adolescents,1978–1997, report from the Automated Childhood Cancer Information System project. Eur J Cancer. 2006;42(2124).
3.
Zurück zum Zitat Haddox CL, Han G, Anijar L, et al. Osteosarcoma in pediatric patients and young adults: a single institution retrospective review of presentation, therapy, and outcome. Sarcoma. 2014;2014:402509.CrossRef Haddox CL, Han G, Anijar L, et al. Osteosarcoma in pediatric patients and young adults: a single institution retrospective review of presentation, therapy, and outcome. Sarcoma. 2014;2014:402509.CrossRef
4.
Zurück zum Zitat Wafa H, Grimer RJ. Surgical options and outcomes in bone sarcoma. Expert Rev Anticancer Ther. 2006;6:239–48.CrossRef Wafa H, Grimer RJ. Surgical options and outcomes in bone sarcoma. Expert Rev Anticancer Ther. 2006;6:239–48.CrossRef
5.
Zurück zum Zitat Meyers PA, Schwartz CL, Krailo MD, et al. Osteosarcoma: the addition of muramyl tripeptide to chemotherapy improves overall survival—a report from the Children's Oncology Group. J Clin Oncol. 2008;26:633–8.CrossRef Meyers PA, Schwartz CL, Krailo MD, et al. Osteosarcoma: the addition of muramyl tripeptide to chemotherapy improves overall survival—a report from the Children's Oncology Group. J Clin Oncol. 2008;26:633–8.CrossRef
6.
Zurück zum Zitat Hawkins MM, Wilson LMK, Burton HS, et al. Radiotherapy, alkylating agents, and risk of bone cancer after childhood cancer. J Natl Cancer Inst. 1996;88:270–8.CrossRef Hawkins MM, Wilson LMK, Burton HS, et al. Radiotherapy, alkylating agents, and risk of bone cancer after childhood cancer. J Natl Cancer Inst. 1996;88:270–8.CrossRef
7.
Zurück zum Zitat Zhong GQ, Tu RH, Zeng ZY, et al. Novel functional role of heat shock protein 90 in protein kinase C-mediated ischemic postconditioning. J Surg Res. 2014;189:198–206.CrossRef Zhong GQ, Tu RH, Zeng ZY, et al. Novel functional role of heat shock protein 90 in protein kinase C-mediated ischemic postconditioning. J Surg Res. 2014;189:198–206.CrossRef
8.
Zurück zum Zitat Klebe S, Durr A, Rentschler A, et al. New mutations in protein kinase C gamma associated with spinocerebellar ataxia type 14. Ann Neurol. 2005;58:720–9.CrossRef Klebe S, Durr A, Rentschler A, et al. New mutations in protein kinase C gamma associated with spinocerebellar ataxia type 14. Ann Neurol. 2005;58:720–9.CrossRef
9.
Zurück zum Zitat Mochizuki H, Seki T, Adachi N, et al. R659S mutation of γPKC is susceptible to cell death: implication of this mutation/polymerp-hism in the pathogenesis of retinitis pigmentosa. Neurochem Int. 2006;49:669–75.CrossRef Mochizuki H, Seki T, Adachi N, et al. R659S mutation of γPKC is susceptible to cell death: implication of this mutation/polymerp-hism in the pathogenesis of retinitis pigmentosa. Neurochem Int. 2006;49:669–75.CrossRef
10.
Zurück zum Zitat Parsons M, Adams JC. Rac regulates the interaction of fascin with protein kinase C in cell migration. J Cell Sci. 2008;121:2805–13.CrossRef Parsons M, Adams JC. Rac regulates the interaction of fascin with protein kinase C in cell migration. J Cell Sci. 2008;121:2805–13.CrossRef
11.
Zurück zum Zitat Mazzoni E, Adam A, Bal de Kier Joffe E, et al. Immortalized mammary epithelial cells overexpressing protein kinase C gamma acquire a malignant phenotype and become tumorigenic in vivo. Mol Cancer Res. 2003;1:776–87.PubMed Mazzoni E, Adam A, Bal de Kier Joffe E, et al. Immortalized mammary epithelial cells overexpressing protein kinase C gamma acquire a malignant phenotype and become tumorigenic in vivo. Mol Cancer Res. 2003;1:776–87.PubMed
12.
Zurück zum Zitat Xie X, Ma YT, Fu ZY, Yang YN, Ma X, Chen BD, et al. Haplotype analysis of the CYP8A1 gene associated with myocardial infarction. Clin Appl Thromb Hemost. 2009;15:574–80.CrossRef Xie X, Ma YT, Fu ZY, Yang YN, Ma X, Chen BD, et al. Haplotype analysis of the CYP8A1 gene associated with myocardial infarction. Clin Appl Thromb Hemost. 2009;15:574–80.CrossRef
13.
Zurück zum Zitat Shi YY, He L. SHEsis, a powerful software platform for analyses of linkage disequilibrium, haplotype construction, and genetic association at polymorphism loci. Cell Res. 2005;15:97–8.CrossRef Shi YY, He L. SHEsis, a powerful software platform for analyses of linkage disequilibrium, haplotype construction, and genetic association at polymorphism loci. Cell Res. 2005;15:97–8.CrossRef
14.
Zurück zum Zitat Li Z, Zhang Z, He Z, et al. A partition-ligation-combination-subdivision EM algorithm for haplotype inference with multiallelic markers: update of the SHEsis (http://analysis.bio-x.cn). Cell Res. 2009;19:519–23.CrossRef Li Z, Zhang Z, He Z, et al. A partition-ligation-combination-subdivision EM algorithm for haplotype inference with multiallelic markers: update of the SHEsis (http://​analysis.​bio-x.​cn). Cell Res. 2009;19:519–23.CrossRef
15.
Zurück zum Zitat Chen C, Kano M, Abeliovich A, et al. Impaired motor-coordination correlates with persistent multiple climbing fiber innervation in PKC gamma mutant mice. Cell. 1995;83:1233–42.CrossRef Chen C, Kano M, Abeliovich A, et al. Impaired motor-coordination correlates with persistent multiple climbing fiber innervation in PKC gamma mutant mice. Cell. 1995;83:1233–42.CrossRef
16.
Zurück zum Zitat Nolte D, Landendinger M, Schmitt E, et al. Spinocerebellar ataxia 14: novel mutation in exon 2 of PRKCG in a German family. Mov Disord. 2007;22:265–7.CrossRef Nolte D, Landendinger M, Schmitt E, et al. Spinocerebellar ataxia 14: novel mutation in exon 2 of PRKCG in a German family. Mov Disord. 2007;22:265–7.CrossRef
17.
Zurück zum Zitat Fahey MC, Knight MA, Shaw JH, et al. Spinocerebellar ataxia type 14: study of a family with an exon 5 mutation in the PRKCG gene. J Neurol Neurosurg Psychiatry. 2005;76:1720–2.CrossRef Fahey MC, Knight MA, Shaw JH, et al. Spinocerebellar ataxia type 14: study of a family with an exon 5 mutation in the PRKCG gene. J Neurol Neurosurg Psychiatry. 2005;76:1720–2.CrossRef
18.
Zurück zum Zitat Hashimoto Y, Parsons M, Adams JC. Dual actin-bundling and protein kinase C-binding activities of fascin regulate carcinoma cell migration downstream of Rac and contribute to metastasis. Mol Biol Cell. 2007;18:4591–602.CrossRef Hashimoto Y, Parsons M, Adams JC. Dual actin-bundling and protein kinase C-binding activities of fascin regulate carcinoma cell migration downstream of Rac and contribute to metastasis. Mol Biol Cell. 2007;18:4591–602.CrossRef
19.
Zurück zum Zitat Vignjevic D, Schoumacher M, Gavert N, et al. Fascin, a novel target of beta-catenin-TCF signaling, is expressed at the invasive front of human colon cancer. Cancer Res. 2007;67:6844–53.CrossRef Vignjevic D, Schoumacher M, Gavert N, et al. Fascin, a novel target of beta-catenin-TCF signaling, is expressed at the invasive front of human colon cancer. Cancer Res. 2007;67:6844–53.CrossRef
20.
Zurück zum Zitat Li Y, Dang TA, Shen J, et al. Identification of a plasma proteomic signature to distinguish pediatric osteosarcoma from benign osteochondroma. Proteomics. 2006;6:3426–35.CrossRef Li Y, Dang TA, Shen J, et al. Identification of a plasma proteomic signature to distinguish pediatric osteosarcoma from benign osteochondroma. Proteomics. 2006;6:3426–35.CrossRef
21.
Zurück zum Zitat Ren L, Hong SH, Cassavaugh J, et al. The actin-cytoskeleton linker protein ezrin is regulated during osteosarcoma metastasis by PKC. Oncogene. 2008;28:792–802.CrossRef Ren L, Hong SH, Cassavaugh J, et al. The actin-cytoskeleton linker protein ezrin is regulated during osteosarcoma metastasis by PKC. Oncogene. 2008;28:792–802.CrossRef
22.
Zurück zum Zitat Koivunen J, Aaltonen V, Koskela S, et al. Protein kinase C α/β inhibitor Go6976 promotes formation of cell junctions and inhibits invasion of urinary bladder carcinoma cells. Cancer Res. 2004;64:5693–701.CrossRef Koivunen J, Aaltonen V, Koskela S, et al. Protein kinase C α/β inhibitor Go6976 promotes formation of cell junctions and inhibits invasion of urinary bladder carcinoma cells. Cancer Res. 2004;64:5693–701.CrossRef
23.
Zurück zum Zitat Taylor J, Pampillo M, Bhattacharya M, Babwah AV. Kisspeptin/KISS1R signaling potentiates extravillous trophoblast adhesion to type-I collagen in a PKC- and ERK1/2-dependent manner. Mol Reprod Dev. 2014;81:42–54.CrossRef Taylor J, Pampillo M, Bhattacharya M, Babwah AV. Kisspeptin/KISS1R signaling potentiates extravillous trophoblast adhesion to type-I collagen in a PKC- and ERK1/2-dependent manner. Mol Reprod Dev. 2014;81:42–54.CrossRef
Metadaten
Titel
Single-nucleotide polymorphisms of the PRKCG gene and osteosarcoma susceptibility
verfasst von
Ying Zhang
Xu Hu
Hong-Kai Wang
Wei-Wei Shen
Tong-Quan Liao
Pei Chen
Tong-Wei Chu
Publikationsdatum
01.12.2014
Verlag
Springer Netherlands
Erschienen in
Tumor Biology / Ausgabe 12/2014
Print ISSN: 1010-4283
Elektronische ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-014-2591-8

Weitere Artikel der Ausgabe 12/2014

Tumor Biology 12/2014 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.